Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 2
1952 1
1953 2
1954 2
1955 7
1956 1
1961 1
1962 3
1963 3
1964 5
1965 5
1966 4
1967 3
1968 8
1969 10
1970 8
1971 6
1972 9
1973 9
1974 5
1975 7
1976 10
1977 8
1978 2
1979 11
1980 11
1981 15
1982 24
1983 24
1984 18
1985 43
1986 30
1987 16
1988 35
1989 34
1990 42
1991 38
1992 47
1993 51
1994 55
1995 65
1996 64
1997 58
1998 73
1999 71
2000 66
2001 69
2002 98
2003 68
2004 80
2005 80
2006 99
2007 97
2008 111
2009 128
2010 139
2011 171
2012 198
2013 206
2014 217
2015 239
2016 242
2017 261
2018 252
2019 228
2020 228
2021 256
2022 257
2023 202

Text availability

Article attribute

Article type

Publication date

Search Results

4,466 results

Results by year

Filters applied: . Clear all
Page 1
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagi… See abstract for full author list ➔ Namkoong H, et al. Among authors: hasegawa y. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: hasegawa y. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses.
Zhu X, Sakamoto S, Ishii C, Smith MD, Ito K, Obayashi M, Unger L, Hasegawa Y, Kurokawa S, Kishimoto T, Li H, Hatano S, Wang TH, Yoshikai Y, Kano SI, Fukuda S, Sanada K, Calabresi PA, Kamiya A. Zhu X, et al. Among authors: hasegawa y. Nat Immunol. 2023 Apr;24(4):625-636. doi: 10.1038/s41590-023-01447-8. Epub 2023 Mar 20. Nat Immunol. 2023. PMID: 36941398
Corrigenda.
Osawa Y, Seki T, Okura T, Takegami Y, Ishiguro N, Hasegawa Y. Osawa Y, et al. Among authors: hasegawa y. Bone Joint J. 2021 Sep;103-B(9):1551. doi: 10.1302/0301-620X.103B9.BJJ-2020-00019. Bone Joint J. 2021. PMID: 34465162 Free PMC article. No abstract available.
Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, Yoneda K, Sekiguchi T, Kawase T, Tsuzuki H, Ishio T, Ara T, Ohigashi H, Nakagawa M, Teshima T. Zhang Z, et al. Among authors: hasegawa y. Bone Marrow Transplant. 2022 May;57(5):775-780. doi: 10.1038/s41409-022-01619-4. Epub 2022 Feb 28. Bone Marrow Transplant. 2022. PMID: 35228711 Free article.
Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Shima D, Gomez R, Pastrak A, Castellanos O. Horikawa R, et al. Among authors: hasegawa y. Horm Res Paediatr. 2022;95(3):275-285. doi: 10.1159/000524600. Epub 2022 Apr 13. Horm Res Paediatr. 2022. PMID: 35417909 Free PMC article. Clinical Trial.
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
Akechi T, Yamaguchi T, Uchida M, Imai F, Momino K, Katsuki F, Sakurai N, Miyaji T, Mashiko T, Horikoshi M, Furukawa TA, Yoshimura A, Ohno S, Uehiro N, Higaki K, Hasegawa Y, Akahane K, Uchitomi Y, Iwata H. Akechi T, et al. Among authors: hasegawa y. J Clin Oncol. 2023 Feb 10;41(5):1069-1078. doi: 10.1200/JCO.22.00699. Epub 2022 Nov 2. J Clin Oncol. 2023. PMID: 36322882 Clinical Trial.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. Among authors: hasegawa y. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A. Tanaka I, et al. Among authors: hasegawa y. J Natl Cancer Inst. 2022 Feb 7;114(2):290-301. doi: 10.1093/jnci/djab183. J Natl Cancer Inst. 2022. PMID: 34524427 Free PMC article.
4,466 results